HIGHLIGHTS
- who: Thrombus et al. from the Carnegie Mellon University have published the research work: Factor XII silencing using siRNA prevents thrombus formation in a rat model of extracorporeal life support, in the Journal: (JOURNAL)
- what: This study determined whether FXII silencing using siRNA can provide sufficient anticoagulation for ECLS, maintain normal tissue coagulation, and reduce the need for careful anticoagulation monitoring. The experiment was continued for eight hours or until the mock-oxygenator blood flow resistance reached three times its baseline resistance and was considered failed. In the current study, a single intravenous dose of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.